Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Advanced NSCLC”

150 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 150 results

Not applicableUnknownNCT03236675
What this trial is testing

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Exosome Diagnostics, Inc. 60
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Testing effectiveness (Phase 2)Looking for participantsNCT05777278
What this trial is testing

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 29
Early research (Phase 1)Active Not RecruitingNCT03707938
What this trial is testing

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaALK Gene RearrangementLung Non-Small Cell Carcinoma+4 more
M.D. Anderson Cancer Center 35
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05384626
What this trial is testing

Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid Tumor
Nuvalent Inc. 840
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Not applicableStudy completedNCT06339554
What this trial is testing

Alectinib-induced Endocrine Toxicity

Who this might be right for
NSCLC Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05955391
What this trial is testing

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 164
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Not applicableActive Not RecruitingNCT04764188
What this trial is testing

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Who this might be right for
NSCLC
Hoffmann-La Roche 800
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT05950139
What this trial is testing

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Who this might be right for
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Early research (Phase 1)Study completedNCT01121575
What this trial is testing

Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Pfizer 70
Next Page